WO2013036610A3 - Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires - Google Patents

Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires Download PDF

Info

Publication number
WO2013036610A3
WO2013036610A3 PCT/US2012/053920 US2012053920W WO2013036610A3 WO 2013036610 A3 WO2013036610 A3 WO 2013036610A3 US 2012053920 W US2012053920 W US 2012053920W WO 2013036610 A3 WO2013036610 A3 WO 2013036610A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
prevention
airway injury
Prior art date
Application number
PCT/US2012/053920
Other languages
English (en)
Other versions
WO2013036610A2 (fr
Inventor
Jianjie Ma
Noah Weisleder
Original Assignee
University Of Medicine And Dentistry Of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Medicine And Dentistry Of New Jersey filed Critical University Of Medicine And Dentistry Of New Jersey
Priority to US14/343,560 priority Critical patent/US20150110778A1/en
Priority to EP12829354.5A priority patent/EP2753363A4/fr
Priority to CN201280056362.1A priority patent/CN104066452A/zh
Publication of WO2013036610A2 publication Critical patent/WO2013036610A2/fr
Publication of WO2013036610A3 publication Critical patent/WO2013036610A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des procédés de traitement et/ou de protection des cellules et/ou des tissus des voies respiratoires de dommages dus à des lésions au niveau des poumons ou de complications de maladies respiratoires, cardiovasculaires ou infectieuses sous-jacentes, ou toute combinaison de ceux-ci.
PCT/US2012/053920 2006-07-11 2012-09-06 Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires WO2013036610A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/343,560 US20150110778A1 (en) 2006-07-11 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury
EP12829354.5A EP2753363A4 (fr) 2011-09-07 2012-09-06 Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires
CN201280056362.1A CN104066452A (zh) 2011-09-07 2012-09-06 治疗和预防气道损伤的含mg53组合物及方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531708P 2011-09-07 2011-09-07
US61/531,708 2011-09-07

Publications (2)

Publication Number Publication Date
WO2013036610A2 WO2013036610A2 (fr) 2013-03-14
WO2013036610A3 true WO2013036610A3 (fr) 2013-05-02

Family

ID=47832768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/053920 WO2013036610A2 (fr) 2006-07-11 2012-09-06 Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires

Country Status (3)

Country Link
EP (1) EP2753363A4 (fr)
CN (1) CN104066452A (fr)
WO (1) WO2013036610A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266551B (zh) * 2016-04-06 2021-03-05 牡丹江友搏药业有限责任公司 一种mg53突变体及其制备方法和应用
JP7144402B2 (ja) 2016-08-01 2022-09-29 ホープ・メディシン（ナンジン）・カンパニー・リミテッド Ｍｇ５３突然変異体、その作製方法、およびその使用
CN107987147A (zh) * 2016-10-26 2018-05-04 王惠琴 一种mg53多聚体制备方法及其用途
CN117982625A (zh) * 2017-03-22 2024-05-07 神济昌华(北京)生物科技有限公司 Trim72在预防或治疗als中的用途
CN107629123B (zh) * 2017-09-07 2020-08-25 北京大学 一种抗mg53蛋白的纳米抗体及应用
CN113474011A (zh) * 2018-12-07 2021-10-01 俄亥俄州立创新基金会 促进角膜组织修复的组合物和方法
EP4003388A4 (fr) * 2019-07-25 2024-05-22 Ohio State Innovation Foundation Composition et procédé pour améliorer la performance tissulaire
WO2021211098A1 (fr) 2020-04-14 2021-10-21 Trim-Edicine, Inc. Prévention et traitement d'une défaillance d'organe induite par une infection virale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
US20090075875A1 (en) * 2006-10-03 2009-03-19 Stanley Hoffman Protection against lung fibrosis by up-regulating the function or expression of caveolin-1
US20110202033A1 (en) * 2006-07-11 2011-08-18 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471815B1 (fr) * 2006-07-11 2016-03-30 University Of Medicine And Dentistry Of New Jersey Protéines, acides nucléiques codant pour celles-ci et procédés d'utilisation correspondants
WO2009073808A2 (fr) * 2007-12-04 2009-06-11 University Of Medicine And Dentistry Of New Jersey Compositions et procédés de modulation du recollage de membranes cellulaires
CN101797375B (zh) * 2009-12-02 2013-01-23 北京大学 Mg53蛋白预防和/或治疗心脏缺血/再灌损伤的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
US20110202033A1 (en) * 2006-07-11 2011-08-18 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury
US20090075875A1 (en) * 2006-10-03 2009-03-19 Stanley Hoffman Protection against lung fibrosis by up-regulating the function or expression of caveolin-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2753363A4 *
ZHU, H. ET AL.: "Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair", JBC, vol. 286, no. 15, 15 April 2011 (2011-04-15), pages 12820 - 12824, XP055066140 *

Also Published As

Publication number Publication date
CN104066452A (zh) 2014-09-24
EP2753363A2 (fr) 2014-07-16
EP2753363A4 (fr) 2015-03-11
WO2013036610A2 (fr) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013036610A3 (fr) Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires
WO2012110770A3 (fr) Composition pharmaceutique
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
IN2014DN09173A (fr)
EP2440209A4 (fr) Compositions et méthodes pour prévenir et traiter une insuffisance cardiaque
GB2503066B8 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2014016548A3 (fr) Composition pharmaceutique
WO2012015986A3 (fr) Dérivés substitués de bioxopipéridinyl phtalimide
HK1186671A1 (en) Formulations for the treatment of disorders of the upper respiratory tract
EP2651439A4 (fr) Compositions et procédés pour le traitement ou la prévention d'une infection par l'adénovirus 36 humain
WO2012007729A3 (fr) Compositions pharmaceutiques
WO2012047951A3 (fr) Cellules souches pulmonaires humaines et leurs utilisations
EP2427061A4 (fr) Formulation de gallium pour le traitement et la prévention de maladies infectieuses
WO2011150190A3 (fr) Composés inhibiteurs du virus de l'hépatite c (hcv) et leurs procédés d'utilisation
WO2012037562A3 (fr) Compositions pharmaceutiques et nutraceutiques d'acide abscisique
EP2496251A4 (fr) Méthodes, composés et compositions pour le traitement et la prophylaxie des voies respiratoires
WO2013117744A3 (fr) Méthodes de traitement de la fibrose
WO2012051339A3 (fr) Procédés et compositions pour traiter des pathologies respiratoires en utilisant du plasma enrichi en plaquettes
EP2594283A4 (fr) Préparation aérosol à base d'aprotinine pour traiter les infections respiratoires virales
WO2012024583A3 (fr) Composés oxystérol
WO2013059233A3 (fr) Compositions thermosensibles à usage dermatologique et méthodes associées
WO2012082942A3 (fr) Analogues de neuropeptides, compositions et procédés pour le traitement de la douleur
EP2608783A4 (fr) Utilisation d'acide glycyrrhétinique, d'acide glycyrrhizique et de composés associés pour prévention et/ou traitement de fibrose pulmonaire
EP2763687A4 (fr) Procédés et compositions pour le traitement d'un syndrome métabolique, de troubles respiratoires obstructifs, du cancer et de maladies associées
WO2014203074A3 (fr) Utilisation de ghréline non acétylée, de ses fragments et ses analogues comme agents antioxydants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829354

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012829354

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14343560

Country of ref document: US